Sanofi and Regeneron said results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.
Researchers at the University of California, San Francisco (UCSF) synthesized a molecule inspired by llama antibodies called nanobodies that could neutralize SARS-CoV-2, the virus that causes Covid-19.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.
According to several studies, the risk of contracting COVID-19 or developing a serious case of the disease may be greater depending on blood type.
CSL Behring is attempting to make a difference in the pandemic in various ways, including harnessing the power of antibodies from the blood of recovered COVID-19 patients.
The U.S. Centers for Disease Control and Prevention (CDC) plans a nationwide study of up to 325,000 people to track how the new coronavirus is spreading across the country into 2021 and beyond, a CDC spokeswoman and researchers conducting the effort told Reuters.
iSpecimen will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.
A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
As COVID-19 spreads across the globe, Vancouver-based AbCellera and Eli Lilly teamed up to co-develop antibody products for the treatment and prevention of the novel coronavirus.